Jin Yang Pharmaceutical Co Ltd

Jin Yang Pharmaceutical Co Ltd maintains a relatively strong liquidity position, with a current ratio of 1.85, indicating that it has sufficient current assets to cover its current liabilities. However, the company's net cash position is negative after subtracting total debt, which introduces a medium liquidity risk. The company's price-to-book ratio of 0.73 suggests that it is trading at a discount to its book value, potentially indicating undervaluation or concerns about asset quality.

In terms of profitability, Jin Yang Pharmaceutical Co Ltd reports a return on equity (ROE) of 2.08% and a return on assets (ROA) of 1.5%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. The company's gross profit margin is 64.0%, which is in line with industry norms, but its operating margin of 8.1% and net margin of 6.8% suggest that it is facing moderate cost pressures or competitive challenges.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification beyond South Korea. This lack of geographic diversification increases the company's exposure to local economic and regulatory conditions, which could impact its long-term stability and growth potential.

Jin Yang Pharmaceutical Co Ltd has reported a revenue of KRW 27.3 billion in the latest period, with a gross profit of KRW 17.5 billion and an operating income of KRW 2.2 billion. The company's outlook for the current fiscal year is neutral, with no significant growth expected in the near term. The company's capital expenditure of KRW -294 million indicates a reduction in investment, which may signal a focus on cost control rather than expansion.

The company's risk assessment indicates a low dilution risk, with no significant dilution potential in the near term. However, the company's net cash position is negative after subtracting total debt, which could necessitate future financing activities that may involve equity dilution. The company's debt-to-equity ratio of 0.09 is relatively low, suggesting a conservative capital structure.

Recent filings and transcripts do not indicate any major strategic shifts or significant events that would impact the company's operations or financial performance in the near term. The company's recent financial performance and risk profile suggest a stable but modest growth trajectory, with limited exposure to external shocks.

Jin Yang Pharmaceutical Co Ltd (007370.KQ) has undergone a significant update to its corporate taxonomy, now formally classified under the "Pharmaceuticals & Medical Research" activity within the broader "Healthcare" economic sector. This reclassification represents a medium-severity change in the company's profile, establishing a clearer framework for understanding its operational focus and industry alignment. Alongside the sectoral definition, the company's risk assessment profile has been initialized with specific metrics. The dilution risk is currently assessed as "low," indicating a stable capital structure with minimal immediate threat of share value erosion from new issuances. This assessment provides a baseline for evaluating the company's equity stability. Conversely, the liquidity risk has been flagged as "medium." This designation suggests that while the company is not in immediate distress, there may be moderate constraints on its ability to meet short-term obligations or trade volume limitations that investors should monitor. This risk level is classified as low severity in terms of immediate impact but remains a key factor in overall financial health. The COMPANY_360 data indicates that Jin Yang Pharmaceutical currently has no reported officers, analysts, index memberships, or top holders in the available dataset. This lack of external coverage or disclosed major stakeholders, combined with the newly established risk and sector profiles, highlights the company as an entity with limited public market visibility and analyst attention at this time.

Revenue grew at a 17.7% CAGR over four years, showing consistent top-line expansion despite recent quarterly fluctuations.

Cash conversion ratio of 1.79 is well above the cohort median of 0.95, highlighting efficient cash generation from operations.

Debt-to-equity ratio of 0.09 is half the cohort median of 0.18, suggesting a conservative capital structure with low leverage risk.

Medium liquidity risk flags suggest potential challenges in meeting short-term obligations, warranting caution regarding financial stability.